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Abstract
This clinical trial summary provides the background and rationale for the JUNIPER study (NCT02152631). JUNIPER is
a randomized study of abemaciclib (200 mg orally every 12 hours) with best supportive care (BSC) versus erlotinib (150
mg orally every 24 hours) with BSC in patients with stage IV nonesmall-cell lung cancer (NSCLC) whose tumors have
detectable Kirsten rat sarcoma (KRAS) mutations and whose disease has progressed after platinum-based chemo-
therapy and 1 other previous therapy, or who are not eligible for further chemotherapy. Approximately 550 patients will
be randomized in a 3:2 ratio and stratiﬁed according to number of previous chemotherapy regimens (1 vs. 2), Eastern
Cooperative Oncology Group performance status (0 vs. 1), sex (male vs. female), and KRAS mutation (G12C vs.
others). Erlotinib was chosen as the control arm, because it is the only agent indicated for second- and third-line
therapy in advanced NSCLC. Treatment will continue until disease progression or unacceptable toxicity occurs,
with assessments every 28 days, followed by short-term and long-term follow-up. The coprimary efﬁcacy objectives of
this study are progression-free survival (PFS) and overall survival (OS); secondary objectives are overall response rate,
changes in patient-reported pain and disease-related symptoms, changes in health status, resource utilization, safety
and tolerability, and pharmacokinetics/pharmacodynamics. This design has 80% power to detect OS hazard ratio (HR)
of 0.75 (type I error 0.045) and PFS HR of 0.67 (type I error 0.005). If the coprimary objectives (OS and PFS) are
achieved, this study will provide a new alternative third-line treatment option for patients with NSCLC whose tumors
have detectable KRAS mutations.
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Introduction
Mutations in the Kirsten rat sarcoma (KRAS) oncogene have been
implicated in the development of nonesmall-cell lung cancer
(NSCLC).1 Patients with metastatic NSCLC who have KRAS mu-
tations (15%-25%)2 have a poor prognosis compared with NSCLC
patients with KRAS wild type.3 Of the KRAS mutations in NSCLC,
approximately 97% occur in codons 12 or 13.4 These mutations lead
to persistent activation of rat sarcoma (RAS) signaling, which con-
tributes to unregulated growth and malignant transformation.
The activity of cyclin-dependent kinase (CDK)-4 is required for
tumor progression in a KRAS-induced lung adenocarcinoma model.
RAS and CDK4 coexpression promotes retinoblastoma protein (Rb)
phosphorylation, ultimately resulting in human invasive neoplasm.5
Ablation of CDK4 selectively induces senescence of KRAS-
expressing cells.6 Therefore, CDK4 might be an attractive drug
candidate for KRAS mutation-positive NSCLC.
Abemaciclib (LY2835219) is a potent and selective small
molecule inhibitor of CDK4 and CDK67 that has been shown to
inhibit cell cycle progression by prevention of phosphorylation and
functional inactivation of the Rb tumor suppressor protein. Abe-
maciclib effectively inhibited growth of cancer cells in cell culture,
and when administered orally, demonstrated single-agent efﬁcacy
in various xenograft models for human cancer including NSCLC.7
In a phase I study (I3Y-MC-JPBA; ClinicalTrials.gov Identiﬁer:
NCT01394016),7 abemaciclib showed acceptable safety and toler-
ability, and evidence of clinical activity in pretreated patients with
multiple tumor types. In one cohort of the study, the KRAS mu-
tation status of tumors from patients with advanced and/or meta-
static NSCLC (n ¼ 57) was identiﬁed (n ¼ 53).8 Among patients
with KRAS mutant tumors (n ¼ 29), 16 patients had a Response
Evaluation Criteria in Solid Tumors (RECIST) response of stable
disease (SD) or better (disease control rate [DCR], 55.2%). For
patients with KRAS wild type tumors (n ¼ 24), 9 had a response of
SD or better (DCR, 37.5%). These ﬁndings led to the current study
design, in which the combination of abemaciclib with bestFigure 1 Study Design
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Q24H ¼ every 24 hours.supportive care (BSC) versus erlotinib with BSC will be evaluated in
pretreated patients with advanced stage NSCLC whose tumors have
a detectable KRAS mutation.
Patients and Methods
Study Objectives
The coprimary objectives of this study are to compare
progression-free survival (PFS) and overall survival (OS) in the 2
study arms. Secondary objectives include the following: to compare
overall response rate (complete response þ partial response); to
investigate the safety and tolerability, and resource utilization (for
example, analgesic type, hospitalizations, transfusions); to evaluate
changes in health status via European Quality of Lifee5
Dimensions-5 Level, and changes in patient-reported pain and
disease-related symptoms collected via the MD Anderson Symptom
Inventory; and to characterize the pharmacokinetics and pharma-
codynamics properties of abemaciclib. The exploratory objectives of
the study are to explore biomarkers relevant to abemaciclib and the
disease state and to correlate these markers with clinical outcome
and to abemaciclib.
Study Design and Treatment
This multicenter, randomized, open-label, parallel, comparator-
controlled trial consists of eligible patients randomized in a 3:2
ratio to 1 of 2 treatment arms. Patients in the abemaciclib arm will
receive 200 mg orally every 12 hours with BSC on days 1 to 28 of a
28-day cycle. Patients in the erlotinib arm will receive 150 mg orally
every 24 hours plus BSC on days 1 to 28 of a 28-day cycle.
Randomization will be stratiﬁed according to differences in factors
thought to be associated with clinical outcomes to further reduce
the potential for bias and improve the power of the analyses. The
study design is shown in Figure 1.
Palliative and supportive care for other disease-related symptoms
and for toxicity associated with treatment will be offered to all pa-
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82 -Rationale for the Erlotinib plus BSC Control Arm
Erlotinib is indicated for the ﬁrst-line treatment of metastatic
NSCLC patients whose tumors have epidermal growth factor re-
ceptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution
mutations. Erlotinib is also approved for the treatment of patients
with locally advanced or metastatic NSCLC after failure of at least 1
previous chemotherapy regimen.9 The use of erlotinib for second-
and third-line treatment has no limitation with regard to EGFR or
KRAS mutation status.
There has been some concern regarding the activity of erlotinib in
the treatment of NSCLC with KRAS mutations because of results
from 3 studies.10-12 First, in the BR-21 study, a subgroup evaluation
of 30 patients with KRAS mutant tumors randomized between pla-
cebo and erlotinib showed a nonsigniﬁcant better survival outcome in
the placebo group.10 In TITAN (Tarceva In Treatment of Advanced
NSCLC), a second-line study of erlotinib versus chemotherapy, in
patients with KRASmutant tumors (n¼ 35) there was some evidence
of a greater risk of death in the erlotinib group (P ¼ .057).11 Last, a
meta-analysis of response rate showed a numerically inferior response
rate in patients with KRAS mutant tumors treated with EGFR
tyrosine kinase inhibitors (such as erlotinib and geﬁtinib).12 How-
ever, the small number of patients in the KRAS mutation subgroups
precluded deﬁnitive conclusions in these trials.
In the TAILOR (Tarceva Italian Lung Optimization Trial) study,
in a comparison of docetaxel and erlotinib as second-line therapy in
advanced NSCLC, there was not a signiﬁcant treatment interaction
based on KRAS status.13 In the SATURN (Sequential Tarceva in
Unresectable NSCLC) study of erlotinib maintenance therapy,
improved PFS was preserved in a subset of 90 patients with KRAS
mutant tumors (hazard ratio [HR], 0.77).14 The DELTA (Docetaxel
and Erlotinib Lung Cancer Trial) study evaluated docetaxel and
erlotinib as second- or third-line therapy in patients unselected for
EGFR status with advanced NSCLC and found no signiﬁcant dif-
ference in PFS between the 2 treatments.15 However, in a subgroup
analysis it was found that PFS and response rates were signiﬁcantly
better with docetaxel in patients with EGFR wild type tumors, and
erlotinib resulted in longer PFS and OS in patients with EGFR
mutant tumors.15 Absence of signiﬁcance in that study was attributed
to the small sample size. Overall, the data remain conﬂicting after
extensive review of the literature. Because of the differences in
toxicity proﬁles for available treatments and the limited treatment
options for patients, erlotinib was considered an acceptable control
arm, because it is the only drug approved by the US Food and Drug
Administration as both second- and third-line treatment of NSCLC,
and may show some preference for EGFR mutant tumors.
Eligibility Criteria
The protocol was approved by each participating institutional
ethics review board. The study will be conducted in accordance with
the ethical principles of the Declaration of Helsinki, and Council for
International Organizations of Medical Sciences International
Ethical Guidelines and good clinical practice. All patients will sign
written informed consent before treatment.
Inclusion criteria include age  18 years of age, conﬁrmed
diagnosis of stage IV NSCLC, and a mutation in codon 12 or 13 of
the KRAS oncogene. Patients must have disease progression after
platinum-based chemotherapy and must have received 1 otherClinical Lung Cancer January 2016previous chemotherapy for advanced and/or metastatic disease or be
judged by the physician as ineligible for further standard second-line
chemotherapy. Patients will be excluded from the study if they have
a personal history of clinically relevant cardiovascular disease, pres-
ence of unstable central nervous system metastasis, or history of any
other signiﬁcant cancer (except nonmelanoma skin cancer or car-
cinoma in situ of the cervix) unless in complete remission with no
therapy for a minimum of 3 years. See Table 1 for a full list of
patient selection criteria.
Statistical Design
The study will enroll approximately 550 patients (330 patients in
the abemaciclib arm and 220 patients in the erlotinib arm). One
interim futility analysis will be performed by an independent data
monitoring committee (DMC). The analysis will occur after 100 PFS
events have been observed, and will be based on PFS. The DMC will
be instructed to recommend the study be stopped for futility if the
observed HR for PFS is> 0.95. The second analyses will be based on
PFS and OS end points to evaluate efﬁcacy. This is the primary PFS
analysis, which will be performed after 338 PFS events have occurred.
The ﬁnal OS analysis will occur when approximately 407 OS events
have been observed. Safety interim analyses will be performed
approximately every 6 months until the ﬁnal OS analysis.
Efﬁcacy analyses will be done on the intention to treat patient
population. All safety summaries and analyses will be based on the
safety population, deﬁned as all enrolled patients who receive at least
1 dose of any study drug. The studywise a level of 0.05 will be split
between the coprimary end points: 0.005 for PFS and 0.045 for OS.
A fallback procedure will be used. The test on PFS will occur
ﬁrst; if the test on PFS is signiﬁcant, the a used for this test will be
added to the 0.045 originally allocated to OS for a total of 0.05.
This fallback procedure will maintain a studywise a level of 0.05.
Because OS data are not anticipated to be mature at the time of the
PFS analysis, 0.001 of the a allocated to OS will be spent at the
time of the PFS analysis. Assuming a PFS HR of 0.67, this sample
size will yield approximately 80% statistical power to detect supe-
riority of the abemaciclib arm over the erlotinib arm with the use of
a 2-sided log rank test and a type I error of 0.005. If the true median
PFS for the erlotinib arm is 2 months, then a HR of 0.67 amounts
to an approximate 1-month improvement in median PFS for the
abemaciclib arm. Assuming an OS HR of 0.75, this sample size will
yield approximately 80% statistical power to detect superiority of
the abemaciclib arm over the erlotinib arm with the use of a 2-sided
log-rank test and a type I error of 0.045. If the true median OS for
the erlotinib arm is 6.5 months, then the HR of 0.75 amounts to an
approximate 2.2-month improvement in median OS for the abe-
maciclib arm.
Conclusion
If the coprimary objectives are achieved, the JUNIPER
(A Randomized Phase 3 Study of Abemaciclib (LY2835219) plus
Best Supportive Care vs. Erlotinib plus Best Supportive Care in
Patients with Stage IV NSCLC with a Detectable KRAS Mutation
Who Have Progressed After Platinum-Based Chemotherapy) study
will provide a new alternative third-line treatment option for pa-
tients with advanced metastatic NSCLC whose tumors have
detectable KRAS mutations.
Table 1 Patient Selection Criteria
Inclusion Criteria
 Conﬁrmed diagnosis of stage IV NSCLC according to the American Joint Committee on Cancer Staging Handbook
 Adequate FFPE tumor-derived material (tumor blocks or slides) from a biopsy, surgery, or ﬁne-needle aspirate for analysis of KRAS mutation status
 Detectable mutations in codons 12 or 13 of the KRAS oncogene
 Disease progression after platinum-based chemotherapy (with or without maintenance therapy) and have received 1 other previous chemotherapy for advanced and/or metastatic disease or is judged by the physician as ineligible for further
standard second-line chemotherapy
 Measureable disease deﬁned according to RECIST
 Performance status of 0 to 1 on the ECOG scale
 Discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents before
receiving study drug
 Recovered from the acute effects of therapy (treatment-related toxicity resolved to baseline) except for residual alopecia
 Adequate organ function
 Men and women aged 18 years
 Male and female patients with reproductive potential must use an approved reliable contraceptive method
 Women with child-bearing potential must have a negative serum pregnancy test at the time of enrollment
 Estimated life expectancy of 12 weeks
 Reliable and willing to follow study procedures
 Signed informed consent and/or assent document
Exclusion Criteria
 Currently enrolled in a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientiﬁcally or medically compatible with this
study
 Received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
 Previously completed or withdrawn from this study or any other study investigating abemaciclib
 Personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia, or sudden cardiac arrest
 Presence of unstable CNS metastasis. History of CNS metastasis or stable CNS metastases are allowed. Patients with a history of CNS metastases must have a brain scan within 28 days of randomization to document stability, even if there
have been no changes in symptoms
 History of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission with no therapy for that disease for a minimum of 3 years
 Serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study
 Women who are pregnant or lactating
 Active bacterial, fungal, and/or known viral infection
Abbreviations: CNS ¼ central nervous system; ECOG ¼ Eastern Cooperative Oncology Group; FFPE ¼ formalin-ﬁxed, parafﬁn-embedded; KRAS ¼ Kirsten rat sarcoma; NSCLC ¼ nonesmall-cell lung cancer; RECIST ¼ Response Evaluation Criteria in Solid Tumors.
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